REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 204 filers reported holding REATA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,769,000 | -72.9% | 67,071 | +3.4% | 0.00% | -75.0% |
| Q3 2021 | $6,525,000 | -28.9% | 64,858 | +0.0% | 0.00% | -33.3% |
| Q2 2021 | $9,177,000 | +173.5% | 64,838 | +92.7% | 0.01% | +200.0% |
| Q1 2021 | $3,355,000 | -21.0% | 33,653 | -2.1% | 0.00% | -33.3% |
| Q4 2020 | $4,248,000 | +27.1% | 34,365 | +0.1% | 0.00% | 0.0% |
| Q3 2020 | $3,343,000 | -37.1% | 34,316 | +0.7% | 0.00% | -40.0% |
| Q2 2020 | $5,318,000 | +44.3% | 34,085 | +33.5% | 0.01% | +25.0% |
| Q1 2020 | $3,685,000 | -42.0% | 25,527 | -17.9% | 0.00% | -33.3% |
| Q4 2019 | $6,356,000 | +169.2% | 31,091 | +5.7% | 0.01% | +200.0% |
| Q3 2019 | $2,361,000 | -21.6% | 29,403 | -7.9% | 0.00% | -33.3% |
| Q2 2019 | $3,011,000 | +10.1% | 31,909 | -0.3% | 0.00% | 0.0% |
| Q1 2019 | $2,735,000 | +18.6% | 31,996 | -22.2% | 0.00% | 0.0% |
| Q4 2018 | $2,307,000 | -6.3% | 41,124 | +36.5% | 0.00% | +50.0% |
| Q3 2018 | $2,463,000 | – | 30,124 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |